How India Exports Sitagliptin to the World

In the United States, Sitagliptin is approved for the treatment of type 2 diabetes mellitus. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Sitagliptin, indicating the presence of generic versions in the market. The regulatory pathway for Sitagliptin involves demonstrating bioequivalence to the reference listed drug, ensuring safety and efficacy. As of March 2026, there are no active FDA import alerts specifically targeting Sitagliptin, suggesting compliance with U.S. regulatory standards. Given that 309 Indian exporters are active in the Sitagliptin market, adherence to FDA regulations is crucial for maintaining market access.

In the European Union, Sitagliptin has been subject to marketing authorizations by the European Medicines Agency (EMA). For instance, Sitagliptin/Metformin Hydrochloride Accord received marketing authorization on July 22, 2022. However, this authorization ceased to be valid on July 22, 2025, as the product was not marketed within three years of approval, invoking the EU's "sunset clause" provisions. This underscores the importance of timely market entry post-authorization. The United Kingdom, post-Brexit, follows its own regulatory framework under the Medicines and Healthcare products Regulatory Agency (MHRA), which aligns closely with EMA standards. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for market access in both regions.

The World Health Organization (WHO) includes Sitagliptin in its Model List of Essential Medicines, recognizing its importance in managing type 2 diabetes mellitus. The 24th edition of the WHO Model List, published in September 2025, lists Sitagliptin as an essential medicine. This inclusion emphasizes the global recognition of Sitagliptin's therapeutic value. Manufacturers are expected to comply with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure product quality and consistency.

In India, Sitagliptin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines under the Drug Price Control Order (DPCO). As of March 2026, Sitagliptin is subject to price control measures to ensure affordability. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products, ensuring that domestic needs are met before permitting exports.

The primary patent for Sitagliptin has expired, allowing for the introduction of generic versions into the market. This has led to increased competition among manufacturers, including Indian exporters, contributing to the availability of cost-effective generic Sitagliptin globally.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming the inclusion of Sitagliptin due to its efficacy in managing type 2 diabetes mellitus. In July 2025, the EMA announced the cessation of validity for the marketing authorization of Sitagliptin/Metformin Hydrochloride Accord, highlighting the critical importance of timely market entry post-authorization. In September 2025, the WHO published the 24th edition of its Model List of Essential Medicines, continuing to list Sitagliptin as an essential medicine, underscoring its global therapeutic significance. In January 2026, the WHO released a fact sheet on essential medicines, emphasizing the need for these medicines to be available, affordable, and of assured quality at all times, reinforcing the importance of compliance with international standards for Sitagliptin manufacturers. In February 2026, the WHO published the report of the 25th Expert Committee on Selection and Use of Essential Medicines, providing detailed insights into the selection process and reaffirming the inclusion of Sitagliptin in the Model List.

These developments highlight the dynamic regulatory landscape for Sitagliptin, emphasizing the need for manufacturers and exporters to stay informed and compliant with international standards and regulations.

India's pharmaceutical industry, including the production of Sitagliptin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of India's API and KSM requirements are sourced from China, underscoring a significant dependency. This reliance exposes the supply chain to vulnerabilities, particularly when Chinese manufacturing faces disruptions due to environmental regulations or geopolitical tensions. For instance, in July 2018, stringent environmental policies led to the shutdown of several Chinese chemical plants, causing supply shortages and price escalations for Indian pharmaceutical companies.

To mitigate this dependency, the Indian government launched the Production Linked Incentive (PLI) scheme in 2020, aiming to bolster domestic API and KSM manufacturing. By November 2024, two greenfield plants were inaugurated under this scheme to produce critical molecules like Penicillin G and Clavulanic Acid, marking a step towards reducing import reliance. However, the effectiveness of these initiatives in achieving self-sufficiency remains to be fully realized.

Our proprietary data indicates that the top five exporters of Sitagliptin from India account for 43.8% of the total export value, with Dr. Reddy's Laboratories Ltd. leading at a 10.2% share. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges. The PLI scheme, while primarily targeting API and KSM production, indirectly supports finished pharmaceutical exports by strengthening the upstream supply chain. As of December 2025, the scheme has attracted significant investments, with 22 greenfield manufacturing projects commissioned, enhancing India's capacity to produce essential medical devices and pharmaceuticals.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical products. Recent geopolitical tensions in these regions have led to increased shipping costs and potential delays. Additionally, escalating US-China trade tensions have raised concerns about the stability of API and KSM supplies. The U.S. Pharmacopeia reported that 41% of key starting materials used in U.S.-approved medicines are solely sourced from China, highlighting the global impact of such dependencies. While specific FDA or EMA shortage alerts for Sitagliptin have not been issued recently, the interconnected nature of the pharmaceutical supply chain necessitates vigilance against potential disruptions.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to invest in local manufacturing capabilities for critical raw materials.

• Strengthen Supply Chain Monitoring: Implement robust systems to monitor geopolitical developments and shipping routes, enabling proactive responses to potential disruptions.

• Develop Strategic Reserves: Establish stockpiles of essential APIs and KSMs to buffer against short-term supply interruptions.

• Foster International Partnerships: Collaborate with global pharmaceutical entities to share resources and information, enhancing collective resilience against supply chain risks.

RISK_LEVEL: MEDIUM